Judge Ruling Favors Calmare® Pain Therapy Reimbursement In Personal Injury Case Against Allstate Insurance Co. Insurance Giant to Reimburse NYC Rehabilitation Center for Its Calmare Therapy Treatments
FAIRFIELD, Conn., June 30, 2014 /PRNewswire/ -- The Calmare® Pain Therapy Device, the flagship product of Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), the pain mitigation company, gained a favorable reimbursement ruling from the New York City Civil Courts in a personal injury case against Allstate Insurance, Co., (Allstate). In the ruling, the Court instructed the insurance giant to reimburse Forest Rehabilitation Medicine P.C. (Forest) for its use of Calmare pain therapy (Calmare) on patients who suffer pain as a result of car accident injuries.
In the New York Civil Court case, Forest Rehabilitation Medicine P.C. v. Allstate Insurance Company, New York Civil Court Judge Theresa Ciccotto rejected Allstate's claim that Calmare, which has been cleared by the U.S. Food and Drug Administration (FDA), is an unproven method. In granting the clinic's bid for the reimbursement, Judge Ciccotto cited the FDA's approval of the treatment and said that she was not concerned about a lack of studies on the long-term effects. This was the first published decision in the U.S. involving the medical necessity of Calmare therapy.
Forest, which has clinics in Staten Island and Brooklyn, last year became the first practice in the United States certified in the treatment. Dominick Gullo of the New York-based law firm, Cassandra & Gullo successfully litigated the case in behalf of Forest.
In the ruling, Judge Ciccotto stated: "It is common knowledge that most if not every type of medication on the market has potential adverse side effects. Anything new ... will inevitably have 'kinks,' which need to be worked out over time. However, this fact should not fuel any unreasonable fear or disapproval of a device which has the potential to literally revolutionize how the medical field addresses and combats chronic pain."
"Judge Ciccotto's decision may be the legal precedent our Nation's chronic pain sufferers have been waiting for," said Competitive Technologies President & CEO Conrad Mir. "Today, about 100 million Americans, one-third of the Nation's population, are plagued by chronic pain. This ruling may help make living pain-free a reality."
For more information on Calmare therapy treatments, please visit: www.calmarett.com or download the Calmare App for iOS or Android.
About Forest Rehabilitation Medicine P.C.
Forest Rehabilitation Medicine P.C. (now known as Calmare Pain Relief Solutions) is a Physician group which specializes in offering a non-narcotic and non-invasive solution for chronic pain. Christopher Perez, MD and Jack D'Angelo, MD, the physicians at Calmare Pain Relief Solutions, specialize in physical medicine and rehabilitation. Together, they have over 30 years of clinical experience treating chronic pain patients suffering from neuropathies such as spinal radiculopathies, post-surgical neuropathic pain, shingles, failed back surgery, Reflex Sympathetic Dystrophy/Chronic Regional Pain Syndrome (RSD/CRPS), and Chemotherapy-induced Peripheral Neuropathy (CIPN).
About the Company
Competitive Technologies Inc., the pain mitigation company, develops and commercializes innovative wound and pain management products and technologies. CTI holds the 510k clearance on its flagship product, the non-invasive Calmare® Pain Therapy Device. The Company is the exclusive licensed global distributor of Calmare.
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
SOURCE Competitive Technologies, Inc.